NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · MAZE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Maze Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.48% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Maze Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.76. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Maze Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 14, 2025 |
| -$1.15-51.32% vs estimate |
| $0.00 |
| Q4 2024 | Mar 31, 2025 | -$18.32-4,171.11% vs estimate | $0.00 |
|---|
| Q3 2024 | Dec 6, 2024 | -$0.06 | $2.50M |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $75.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$50.57-$0.28 (-0.54%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$45.23+$0.98 (+2.21%)
Septerna Inc’s quoted price sits in the upper half of its reported 52-week range, 11.49% below the high.
$3.10$0.00 (0.0%)
Ardelyx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.1% below the high.
$9.52-$0.30 (-3.05%)
DiaMedica Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.64% below the high.
$5.94$0.00 (0.0%)
BioAge Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.12% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
